세계의 지카바이러스 치료제 시장 보고서(2025년)

Zika virus therapeutics refer to medical treatments, drugs, or therapies designed to prevent or manage Zika virus infection, which is primarily transmitted through mosquito bites and can cause symptoms such as fever, rash, and joint pain. Treatment for Zika virus is mainly supportive, focusing on symptom relief, hydration, and monitoring for severe complications, including congenital Zika syndrome in newborns.

The primary product types for Zika virus therapeutics include acetaminophen and other non-steroidal anti-inflammatory drugs (NSAIDs). Acetaminophen is a commonly used pain reliever and fever reducer for managing mild to moderate pain and fever. These therapeutics are classified based on vaccine type, including inactivated vaccines, subunit vaccines, live-attenuated vaccines, and other vaccine types. They are administered in various healthcare settings, such as hospitals, clinics, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The zika virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides zika virus therapeutics market statistics, including the zika virus therapeutics industry global market size, regional shares, competitors with the zika virus therapeutics market share, detailed zika virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the zika virus therapeutics industry. This zika virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The zika virus therapeutics market size has grown strongly in recent years. It will grow from $30.22 billion in 2024 to $32.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the high incidence rate of infection, the disease burden of zika virus infection and associated comorbidities, the rising demand for preventive measures, the growing importance of public health campaigns, and the expansion of global health initiatives.

The zika virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $40.3 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising adoption of clinical trials, increasing demand for therapeutics in zika endemic regions, a rise in investment in R&D, availability of serology kits for qualitative diagnosis, and an increase in alternate programs. Major trends in the forecast period include technological advancements in antiviral drug development, development of serological testing, technological innovations in monoclonal antibodies, development of novel therapies, and technological advancements in rapid diagnostics.

The forecast of 5.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of multiplex Polymerase Chain Reaction test kits and antiviral research reagents sourced from France and Brazil, thereby delaying outbreak responses and elevating public health laboratory expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing infection rates are expected to drive the expansion of the Zika virus therapeutics market. Infection rates refer to the likelihood of disease transmission within a population over a specific period. The rising incidence of Zika infections is driven by inadequate vector control, environmental conditions that promote mosquito breeding, and limited access to preventive healthcare in affected regions. This surge in infections creates a demand for effective Zika virus therapeutics, prompting investment in vaccines and treatments to mitigate the growing public health threat. For example, in December 2024, the UK Health Security Agency, a UK-based government organization, reported that between January and June 2024, there were eight confirmed cases of the Zika virus, a 700% increase compared to the same period in 2023. As a result, the rising infection rate is expected to propel the Zika virus therapeutics market.

Leading companies in the Zika virus therapeutics market are advancing innovative vaccine technologies, such as second-generation adjuvanted inactivated vaccines, to improve immune responses, enhance efficacy, and provide longer-lasting protection. Second-generation adjuvanted inactivated vaccines combine an inactivated virus with an immune-boosting adjuvant to strengthen the body's immune defense against infections. For instance, in March 2024, Valneva SE, a France-based biotechnology company specializing in vaccine production, initiated Phase 1 clinical trials for VLA1601. This highly purified inactivated vaccine candidate targets the Zika virus (ZIKV) and is developed using the same manufacturing platform as Valneva's licensed Japanese encephalitis vaccine, IXIARO. The vaccine is formulated with adjuvants to enhance immune response, which is critical for its effectiveness.

In September 2024, Indian Immunologicals, an India-based vaccine manufacturer, partnered with the Indian Council of Medical Research to develop a cost-effective Zika virus vaccine. This collaboration highlights the importance of creating affordable and accessible vaccines for emerging viral diseases, particularly Zika, which poses significant risks to pregnant women. The Indian Council of Medical Research is India's apex body for biomedical research, focusing on developing safe and effective vaccines to combat public health threats.

Major players in the zika virus therapeutics market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Moderna Inc., DiaSorin S.p.A., Emergent BioSolutions Inc., ARUP Laboratories, Valneva SE, Bharat Biotech International Limited, Euroimmun AG, Tiangen Biotech Co. Ltd., Creative Diagnostics, Inovio Pharmaceuticals Inc., GeoVax Labs Inc., Moleculin Biotech Inc., BioVaxys Technology Corp., Kimer Med Limited, LumiQuick Diagnostics Inc.

North America was the largest region in the zika virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in zika virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zika virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The zika virus therapeutics market consists of sales of vaccines, antiviral drugs and antibody based therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Zika Virus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on zika virus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for zika virus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The zika virus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Acetaminophen; Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 2) By Vaccine Type: Inactivated Vaccine; Subunit Vaccine; Live-Attenuated Vaccine; Other Vaccine Types
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Acetaminophen: Oral Tablets; Oral Suspensions; Intravenous Formulations
• 2) By Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Aspirin; Naproxen; Celecoxib
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Moderna Inc.; DiaSorin S.p.A.; Emergent BioSolutions Inc.; ARUP Laboratories; Valneva SE; Bharat Biotech International Limited; Euroimmun AG; Tiangen Biotech Co. Ltd.; Creative Diagnostics; Inovio Pharmaceuticals Inc.; GeoVax Labs Inc.; Moleculin Biotech Inc.; BioVaxys Technology Corp.; Kimer Med Limited; LumiQuick Diagnostics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Zika Virus Therapeutics Market Characteristics

3. Zika Virus Therapeutics Market Trends And Strategies

4. Zika Virus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Zika Virus Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Zika Virus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Zika Virus Therapeutics Market Growth Rate Analysis
• 5.4. Global Zika Virus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Zika Virus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Zika Virus Therapeutics Total Addressable Market (TAM)

6. Zika Virus Therapeutics Market Segmentation

• 6.1. Global Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acetaminophen
• Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.2. Global Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccine
• Subunit Vaccine
• Live-Attenuated Vaccine
• Other Vaccine Types
• 6.3. Global Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Zika Virus Therapeutics Market, Sub-Segmentation Of Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Suspensions
• Intravenous Formulations
• 6.5. Global Zika Virus Therapeutics Market, Sub-Segmentation Of Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Aspirin
• Naproxen
• Celecoxib

7. Zika Virus Therapeutics Market Regional And Country Analysis

• 7.1. Global Zika Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Zika Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Zika Virus Therapeutics Market

• 8.1. Asia-Pacific Zika Virus Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Zika Virus Therapeutics Market

• 9.1. China Zika Virus Therapeutics Market Overview
• 9.2. China Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Zika Virus Therapeutics Market

• 10.1. India Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Zika Virus Therapeutics Market

• 11.1. Japan Zika Virus Therapeutics Market Overview
• 11.2. Japan Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Zika Virus Therapeutics Market

• 12.1. Australia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Zika Virus Therapeutics Market

• 13.1. Indonesia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Zika Virus Therapeutics Market

• 14.1. South Korea Zika Virus Therapeutics Market Overview
• 14.2. South Korea Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Zika Virus Therapeutics Market

• 15.1. Western Europe Zika Virus Therapeutics Market Overview
• 15.2. Western Europe Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Zika Virus Therapeutics Market

• 16.1. UK Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Zika Virus Therapeutics Market

• 17.1. Germany Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Zika Virus Therapeutics Market

• 18.1. France Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Zika Virus Therapeutics Market

• 19.1. Italy Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Zika Virus Therapeutics Market

• 20.1. Spain Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Zika Virus Therapeutics Market

• 21.1. Eastern Europe Zika Virus Therapeutics Market Overview
• 21.2. Eastern Europe Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Zika Virus Therapeutics Market

• 22.1. Russia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Zika Virus Therapeutics Market

• 23.1. North America Zika Virus Therapeutics Market Overview
• 23.2. North America Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Zika Virus Therapeutics Market

• 24.1. USA Zika Virus Therapeutics Market Overview
• 24.2. USA Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Zika Virus Therapeutics Market

• 25.1. Canada Zika Virus Therapeutics Market Overview
• 25.2. Canada Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Zika Virus Therapeutics Market

• 26.1. South America Zika Virus Therapeutics Market Overview
• 26.2. South America Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Zika Virus Therapeutics Market

• 27.1. Brazil Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Zika Virus Therapeutics Market

• 28.1. Middle East Zika Virus Therapeutics Market Overview
• 28.2. Middle East Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Zika Virus Therapeutics Market

• 29.1. Africa Zika Virus Therapeutics Market Overview
• 29.2. Africa Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Zika Virus Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Zika Virus Therapeutics Market Competitive Landscape
• 30.2. Zika Virus Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Zika Virus Therapeutics Market Other Major And Innovative Companies

• 31.1. Moderna Inc.
• 31.2. DiaSorin S.p.A.
• 31.3. Emergent BioSolutions Inc.
• 31.4. ARUP Laboratories
• 31.5. Valneva SE
• 31.6. Bharat Biotech International Limited
• 31.7. Euroimmun AG
• 31.8. Tiangen Biotech Co. Ltd.
• 31.9. Creative Diagnostics
• 31.10. Inovio Pharmaceuticals Inc.
• 31.11. GeoVax Labs Inc.
• 31.12. Moleculin Biotech Inc.
• 31.13. BioVaxys Technology Corp.
• 31.14. Kimer Med Limited
• 31.15. LumiQuick Diagnostics Inc.

32. Global Zika Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Zika Virus Therapeutics Market

34. Recent Developments In The Zika Virus Therapeutics Market

35. Zika Virus Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Zika Virus Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Zika Virus Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Zika Virus Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer